Watch More Highlights
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses findings from the MagnetisMM-1 trial on elranatamab, a humanized bispecific molecule that targets BCMA expressed in multiple myeloma and engages CD3 on T cells. The results, of interest to advanced practitioners, support continued development of elranatamab as a single agent and in combination with standard treatments for patients with relapsed or refractory multiple myeloma (Abstract 895).